Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Axitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 19/20 | 0.88 |
| ▸ | FLT1 known ✓ | P17948 | 3/20 | 0.88 |
| ▸ | FLT4 known ✓ | P35916 | 3/20 | 0.88 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.88 |
| ▸ | LCK | P06239 | 3/20 | 0.88 |
| ▸ | PLK4 | O00444 | 2/20 | 0.88 |
| ▸ | AURKA | O14965 | 2/20 | 0.88 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.88 |
| ▸ | PAK4 | O96013 | 2/20 | 0.88 |
| ▸ | ABL1 | P00519 | 2/20 | 0.88 |
| ▸ | CSF1R | P07333 | 2/20 | 0.88 |
| ▸ | RET | P07949 | 2/20 | 0.88 |
| ▸ | MET | P08581 | 2/20 | 0.88 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.88 |
| ▸ | KIT | P10721 | 2/20 | 0.88 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.88 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.88 |
| ▸ | TYK2 | P29597 | 2/20 | 0.88 |
| ▸ | AXL | P30530 | 2/20 | 0.88 |
| ▸ | BLK | P51451 | 2/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Axitinib SCHEMBL23044964 | 1.00 | KDR (0.88) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL2826667 | 0.94 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL29349703 | 0.94 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL29387511 | 0.94 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL843204 | 0.94 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL29384419 | 0.94 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL172918 | 0.94 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL5248175 | 0.93 | KDR (0.98) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL5248178 | 0.93 | KDR (0.98) | KDRFGFR1FLT1FLT4LCK | |
| SCHEMBL24503457 | 0.89 | KDR (0.84) | KDRFGFR1FLT1FLT4LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724117-A2 | METHOD OF TREATING AN ARTICULAR CONDITION OR A CONDITION OF A BONY CANAL | Ocular Therapeutix, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4706652-A2 | OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR | Ocular Therapeutix, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4252725-B1 | OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR | OCULAR THERAPEUTIX INC (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250332094-A1 | OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR | OCULAR THERAPEUTIX INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12453724-B2 | Ocular implant containing a tyrosine kinase inhibitor | OCULAR THERAPEUTIX, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250235438-A1 | OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITORI | OCULAR THERAPEUTIX INC (US) | 2025-07-24 | — | — | US | disclosed |
| US-12357565-B2 | Ocular implant containing a tyrosine kinase inhibitor | OCULAR THERAPEUTIX, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| CN-115461040-B | Ophthalmic implant containing tyrosine kinase inhibitor | 视尔普斯眼科公司 | 2025-04-01 | — | — | CN | disclosed |
| WO-2024254258-A2 | METHOD OF TREATING AN ARTICULAR CONDITION OR A CONDITION OF A BONY CANAL | OCULAR THERAPEUTIX, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20230390189-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT | OCULAR THERAPEUTIX, INC. | 2023-12-07 | — | — | US | disclosed |
| EP-4236943-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE AGENT | Ocular Therapeutix, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3884929-B1 | OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR | OCULAR THERAPEUTIX INC (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230118774-A1 | OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR | OCULAR THERAPEUTIX, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11534396-B2 | Methods of treatment with an ocular implant containing a tyrosine kinase inhibitor | OCULAR THERAPEUTIX, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| CN-115461040-A | Ophthalmic implant containing tyrosine kinase inhibitor | 视觉治疗股份有限公司 | 2022-12-09 | — | — | CN | disclosed |
| US-20220347094-A1 | OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR | OCULAR THERAPEUTIX, INC. | 2022-11-03 | — | — | US | disclosed |
| US-11439592-B2 | Ocular implant containing a tyrosine kinase inhibitor | OCULAR THERAPEUTIX, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-11400089-B2 | Multikinase inhibitors and uses in reproductive and digestive tract fibrosis | Dan-Shya Tang-Liu, Diane (US) | 2022-08-02 | — | — | US | disclosed |
| WO-2022093818-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE AGENT | OCULAR THERAPEUTIX, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20220079876-A1 | OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR | OCULAR THERAPEUTIX, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390189-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT | ERBB2, BTK, ERBB3 | KDR 33/4885FLT1 73/4885FLT4 167/4885 |
| US-20250235438-A1 | OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITORI | ERBB3, AXL, ERBB2 | KDR 15/4885FLT1 12/4885FLT4 29/4885 |
| US-20220347094-A1 | OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR | ERBB2, TYRO3, BTK | KDR 23/4885FLT1 24/4885FLT4 45/4885 |
| US-20250332094-A1 | OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR | ERBB2, TYRO3, BTK | KDR 23/4885FLT1 24/4885FLT4 45/4885 |
| US-12453724-B2 | Ocular implant containing a tyrosine kinase inhibitor | ERBB3, ERBB2, AXL | KDR 13/4885FLT1 15/4885FLT4 19/4885 |
| US-20220079876-A1 | OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR | ERBB2, TYRO3, BTK | KDR 23/4885FLT1 24/4885FLT4 45/4885 |
| US-20230118774-A1 | OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR | ERBB2, TYRO3, BTK | KDR 23/4885FLT1 24/4885FLT4 45/4885 |
| US-12357565-B2 | Ocular implant containing a tyrosine kinase inhibitor | ERBB2, TYRO3, BTK | KDR 23/4885FLT1 24/4885FLT4 45/4885 |
| US-11534396-B2 | Methods of treatment with an ocular implant containing a tyrosine kinase inhibitor | BTK, TYRO3, ERBB2 | KDR 43/4885FLT1 39/4885FLT4 48/4885 |
| US-11439592-B2 | Ocular implant containing a tyrosine kinase inhibitor | ERBB2, TYRO3, BTK | KDR 23/4885FLT1 24/4885FLT4 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.